Chabanon et al. demonstrated that cytotoxic doses of the PARPis olaparib and rucaparib induced DNA damage and cGAS-STING-dependent type I IFN signaling in both a BRCA1-deficient TNBC cell line, and lung cancer cells lacking the excision repair cross-complementation groups 1 (ERCC1) protein, a common DDR defect in non-small-cell lung cancers (NSCLC) [105]. This evidence concerns the gene CGAS and non-small cell lung carcinoma.